Acquired Immune Deficiency Syndrome (AIDS) was recognized in 1981 as a new syndrome capable of destroying the human beings. The sudden appearance of the epidemic among previously known rare diseases was soon recognized on the basis of its association with immune- suppressant characteristics, henceforth unrecorded in human history.

As a result of the first case of HIV / AIDS was diagnosed in Pakistan (1987), a research study was initiated to determine the status of HIV / AIDS in the province of Sindh, Pakistan. Surprisingly, in a group of 956 (High risk) individuals using ELISA and Western Blot (WB) techniques, seven (7) HIV-1 and four (4) HIV-2 cases were screened out whereas sixteen (16) individuals were found out as Indeterminate cases [ref: 1]

In 1994, a Medical Research Collaborative Project was initiated between the Ministry of Health, government of Japan and Pakistan, entitled: "Epidemiological Studies on Viral Infections through Blood Transfusion in Asian Countries" for which Dr. Muhammad Rafiq and Dr. Asim Awan were selected as members of the Project by the Japanese Government. Nagoya University, School of Medicine [ref: 2 & 3], under this project offered to extend the research facilities for anti HIV drug screening [ref: 4] more..

This drug carries a hope and message of health to the HIV / AIDS patients all over the world. It is cost effective and easily administered orally in capsule form, it is a patients friendly drug having no side effects.

The drug was administered to 31 HIV AIDS patients with a marked degree of success and remarkable improvement in constitutional symptoms. Twenty Six (26) individuals showed full recovery and their virus load was found below quantitation limits or HIV-RNA not detected by PCR, (both quantitative and qualitative). This success was achieved in most of the patients within 6 to 18 months of the treatment (please see patients reports)